Results 161 to 170 of about 74,341 (223)

Differential <i>in vivo</i> tyrosine kinase inhibitor sensitivities of pediatric ABL-class Ph-like B-acute lymphoblastic leukemia. [PDF]

Hemasphere
Sharma R, Dardis JK, Mai HA, Arenas Merizalde C, van de Ven C, Bárcenas López DA, Bhatnagar S, Attarbaschi A, Boer JM, den Boer ML, Tasian SK.   +10 more
europepmc   +1 more source

Two novel e13a3 variants detected in CML patients and their DNA breakpoint analysis. [PDF]

Front Oncol
Liang D, Chang J, Xu Z, Ren F, Yang B, Chen X, Wang H.   +6 more
europepmc   +1 more source

Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis. [PDF]

Oncologist
Wang S, Lei Y, Liu S, Zhang B, Zhao X, Qiao C, Hong M, Qian S, Fan L, Zhu Y.   +9 more
europepmc   +1 more source

Correction: Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib <i>in vitro</i> and reduces disease burden <i>in vivo</i>. [PDF]

Front Pharmacol
Rajamani BM, Illangeswaran RSS, Benjamin ESB, Balakrishnan B, Jebanesan DZP, Das S, Pai AA, Vidhyadharan RT, Mohan A, Karathedath S, Abraham A, Mathews V, Velayudhan SR, Balasubramanian P.   +13 more
europepmc   +1 more source

<i>KCTD5::PDGFRB</i> Fusion Gene Leading to Clonal Hypereosinophilia With Cardiac Involvement in a Young Adult: A Case Report. [PDF]

Case Rep Hematol
de Groote L, Papazoglou D, Ku J, Heimann P, Dewispelaere L, Sidon P, Roufosse F, Trépant AL, Cilla N.   +8 more
europepmc   +1 more source

Recurrence‑related factors after discontinuation of adjuvant imatinib in intermediate‑ and high‑risk GIST: a retrospective cohort study. [PDF]

BMC Gastroenterol
Huang Y, Zheng X, Gao L, Cao L, Li Z, Chen H, Chen L, Tao L, Wang M, Tao T, Guan W, Wang F.   +11 more
europepmc   +1 more source

Evaluation of Imatinib and Its Combination With Albendazole Against <i>Echinococcus granulosus</i> Protoscoleces and Microcysts In Vitro. [PDF]

J Parasitol Res
Hanifeh Z, Haniloo A, Torabi N, Farhadi M.   +3 more
europepmc   +1 more source

Integrating Asciminib into the Evolving Treatment Landscape of Chronic Myeloid Leukemia: A Canadian Perspective. [PDF]

J Blood Med
Kim DDH, Busque L, Hillis C, Laneuville P, Savoie ML.   +4 more
europepmc   +1 more source